Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2012

View Archived Issues

Pilot trial evaluates rebamipide in aspirin-induced small bowel damage

Japanese study supports in vivo antitumor activity of Golgi-disrupting agent

Xenon Pharmaceuticals enters alliance for pain therapeutics

Sangamo BioSciences begins two phase II trials in HIV

JNK inhibitor prevents hearing loss due to transient cochlear ischemia in preclinical study

Researchers describe role of Th17 cells in vaccine-induced immunity

Chinese company patents new receptor tyrosine kinase inhibitors

Janssen Pharmaceutica patents novel antifungal agents

Baxter submits supplemental BLA to FDA for Gammagard Liquid

Isis Pharmaceuticals reports phase I data on ISIS-TTRRx

University of Arkansas discloses novel vaccine vectors for Campylobacter infections

Tetragenetics flu vaccine protects against H5N1 in preclinical study

HGS provides pipeline update and goals for 2012

Novel serine/threonine-protein kinase PAK inhibitors patented by Afraxis

Guilin Sanjin Pharmaceutical claims novel saponins

Celtaxsys obtains anti-inflammatory drug from Estrellita Pharmaceuticals

Akinion begins treatment in phase I/II AKN-028 study

Scientists at Gene Signal disclose new peptides for wound healing

Lexicon Pharmaceuticals reports topline data from LX-4211/sitagliptin combination trial

Forma Therapeutics enters into exclusive alliance

EC adopts opinion on pioglitazone-containing drugs

Akebia Therapeutics spin-out company created

Biocon reports phase III data on immunotherapy for chronic plaque psoriasis

Cynapsus Therapeutics reports encouraging first-in-human data on APL-130277

Kadmon acquires anticancer candidate from Concordia Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...